|
The content on or accessible through Medpedia.com is for informational purposes only. Medpedia is not a substitute for professional advice or expert medical services from a qualified health professional.
Read more
|
Denosumab
Ask a Question on This Topic
Important Resources for Denosumab:
==Other Names==Template:Prolia, AMG 162
Prefix Target Source Common Suffix
substem A substem B
Deno s u mab is a human monoclonal antibody for the bones
Innovator bones human monoclonal antibody choice
This is a "stub" page. Help expand Medpedia's knowledgebase by Editing or Suggesting Changes to make it more complete.
Denosumab is a fully human monoclonal antibody which binds to Receptor Activator for Nuclear Factor k B Ligand(RANKL) thus preventing the activation of RANKL. The activation of RANKL pathway discoverd by Amgen scientists plays an important role in the pathogenesis of osteoporosis, rheumatoid arthritis, certain cancer and modulation of the immune system. Inhibition of RANKL results in inhibition of oseoclasts formation, function and survival. Osteoclasts play a key regulatory role in bone loss during menopause and after hormone abelation therapy in prostate and breast cancer.
A type of monoclonal antibody being studied in the treatment of multiple myeloma (a cancer that forms in bones) and in the prevention and treatment of bone metastases (cancer that has spread to bone from another organ). Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Denosumab binds to the protein RANKL and helps keep bone from breaking down. Also called AMG 162.[[Category:|Category:]]
To suggest changes to this page, you must create an account on Medpedia.